A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer
Clinical trial NCT02137343 · TERMINATED
Trial details
- NCT number
- NCT02137343
- Sponsor
- Amgen
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-01
- Primary completion
- 2015-06-01
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.